A Trial of HBM9378 in Healthy Chinese Subjects

A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Phase I Clinical Study in Healthy Chinese Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of HBM9378 (SKB378) After Subcutaneous Administration.

The objective is to evaluate the safety, tolerability and pharmacokinetic profile of a single subcutaneous injection of HBM9378 (SKB378) at different doses in healthy Chinese subjects.

Study Overview

• Status: Completed
• Conditions: Asthma
• Intervention / Treatment: Drug: HBM9378 (SKB378) Injection; Drug: Placebo

Detailed Description

The study will consist of one dose esclation part with a total of 5 dose levels. The Subjects will be randomized to receive HBM9378 as reflected by the guiding principle for the dose esclation/expansion phase. Each dose group includes a screening period, a baseline period, an observational period, and a safety follow-up period.

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Chengdu
    • Sichuan, Chengdu, China
      • The Fifth People's Hospital of Chengdu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Written informed consent must be obtained.
2. Healthy Chinese male and female subjects aged 18 to 50 years (both included) are enrolled, no clinically significant abnormalities.
3. Total body weight ≥45kg at screening, and body mass index(BMI)between 18 and 28 kg/m2 (inclusive).
4. Female subjects must meet one of the following criteria for participation in this study: Of non-childbearing potential ;
5. Male subjects and female subjects of childbearing potential must use an effective contraceptive method during their participation in this clinical study.
6. Can communicate successfully with the investigator and understand and comply with the requirements of this study.

Exclusion Criteria:

1. History of relevant allergy/hypersensitivity.

2. History of any of the following diseases:

   1. Any clinically significant comorbidity, as judged by the investigator.
   2. Clinical signs of active infection found at screening.
   3. Previous malignancy within the past 5 years.
   4. Acute or chronic bronchospastic disease within the past 3 years.
3. Subject who are currently suffering from any medical condition.
4. Subjects who have undergone organ transplantation.
5. Received immunosuppressive therapy within 6 months prior to randomization.
6. Received any biological product within 90 days or 5 half-lives (for other study drugs), whichever is longer, prior to randomization, or participated in another clinical study and received a study drug.
7. Received any drug within 4 weeks prior to randomization.
8. Subjects who had an immunization within 4 weeks prior to randomization; subjects who are scheduled to have an immunization during the study or within 4 weeks after the end of study.
9. Donated or lost 400 mL or more blood, or received transfusion of blood or any blood product within 60 days prior to randomization.
10. Subjects who are smokers or have used tobacco or nicotine-containing products within 3 months prior to randomization.
11. Subjects who regularly consumed alcohol within 3 months prior to screening, or who had consumed alcohol after screening and before administration.
12. Subjects who had been exposed to a tuberculosis (TB) patient within 6 months prior to randomization.
13. Subjects who had drug abuse or a positive urine drug screen within 12 months prior to randomization.
14. Pregnant or lactating women.
15. Positive hepatitis B surface antigen (HBsAg) or hepatitis C antibody test result, or clinically significantly abnormal syphilis serology test result.
16. History of immunodeficiency disease, including clinically significantly abnormal HIV antibody test result.
17. Clinically significantly abnormal vital signs, physical examination, chest radiography, electrocardiogram , or laboratory tests , as judged by the investigator.
18. In the investigator's judgment, may increase the risk to the subject.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HBM9378 (SKB378) Injection; Dose: 20 mg/60 mg/200 mg/600 mg/900 mg Frequency: Once Injection subcutaneously	Drug: HBM9378 (SKB378) Injection; Strength: 225 mg (1.5 mL)/vial
Placebo Comparator: Placebo; Dose: 20 mg/60 mg/200 mg/600 mg/900 mg Frequency: Once Injection subcutaneously	Drug: Placebo; Strength: 225 mg (1.5 mL)/vial

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events	Incidence and severity of adverse events	Strat of Treatment to end of study (approsimately 160days)
Pharmacokinetics-AUC0-last	Area under the concentration-time curve from time 0 to last time point after HBM9378 administration	Strat of Treatment to end of study (approsimately 160days)
Pharmacokinetics-Tmax	Time to Cmax of HBM9378	Strat of Treatment to end of study (approsimately 160days)
Pharmacokinetics-Cmax	Maximum observed concentration of HBM9378	Strat of Treatment to end of study (approsimately 160days)
Pharmacokinetics-CL/F	Apparent clearance of HBM9378	Strat of Treatment to end of study (approsimately 160days)
Pharmacokinetics-Vd/F	Apparent volume of distribution during terminal phase of HBM9378	Strat of Treatment to end of study (approsimately 160days)
Pharmacokinetics-T1/2	Terminal elimination half-life of HBM9378	Strat of Treatment to end of study (approsimately 160days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunogenicity	The percentage of patients with anti-drug antibodies after administration.	Strat of Treatment to end of study (approsimately 160days)

Collaborators and Investigators

• Sponsor: Harbour BioMed (Guangzhou) Co. Ltd.

Publications and helpful links

General Publications

• Yang X, Xu M, Cao N, Zhao S, Wei Y, Lu J, Luo R, Ge J, Tao X, He W. Safety, Tolerability, and Pharmacokinetics of HBM9378 (SKB378/WIN378), a Fully Human IgG1 Monoclonal Antibody Against TSLP After Single Ascending Doses in Chinese Healthy Subjects. Drug Des Devel Ther. 2026 Mar 18;20:538649. doi: 10.2147/DDDT.S538649. eCollection 2026.

Study record dates

Study Major Dates

• Study Start (Actual): September 23, 2022
• Primary Completion (Actual): October 24, 2023
• Study Completion (Actual): October 24, 2023

Study Registration Dates

• First Submitted: February 27, 2023
• First Submitted That Met QC Criteria: March 16, 2023
• First Posted (Actual): March 30, 2023

Study Record Updates

• Last Update Posted (Actual): May 1, 2026
• Last Update Submitted That Met QC Criteria: April 27, 2026
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Respiratory Tract Diseases; Lung Diseases; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Asthma; Therapeutics; Drug Administration Routes; Drug Therapy; Injections
• Other Study ID Numbers: 9378.1

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No